Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.36 |
| ▸ | KIT | P10721 | 6/20 | 0.36 |
| ▸ | KDR | P35968 | 6/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.36 |
| ▸ | TOP1 | P11387 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307646 | 1.00 | FLT3 (0.38) | FLT3MEN1KMT2APDGFRBKIT | |
| SCHEMBL4301864 | 0.91 | KCNJ1 (0.47) | FLT3PDGFRBKITKDRKCNJ1 | |
| SCHEMBL4301862 | 0.91 | KCNJ1 (0.47) | FLT3PDGFRBKITKDRKCNJ1 | |
| SCHEMBL4303525 | 0.89 | DRD2 (0.40) | DRD2DRD4KCNJ1KCNH2DRD3 | |
| SCHEMBL6104466 | 0.89 | DRD2 (0.40) | DRD2DRD4KCNJ1KCNH2DRD3 | |
| SCHEMBL4305103 | 0.89 | LRRK2 (0.43) | FLT3PDGFRBKITKDRKCNJ1 | |
| SCHEMBL4305106 | 0.89 | LRRK2 (0.43) | FLT3PDGFRBKITKDRKCNJ1 | |
| SCHEMBL4311506 | 0.88 | LRRK2 (0.46) | FLT3PDGFRBKITKDRIDO1 | |
| SCHEMBL4311501 | 0.88 | LRRK2 (0.46) | FLT3PDGFRBKITKDRIDO1 | |
| SCHEMBL4302869 | 0.87 | PDGFRB (0.40) | PDGFRBKDRTOP1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120238558-A9 | Kinase inhibitors | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120238558-A9 | Kinase inhibitors | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120238558-A9 | Kinase inhibitors | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| WO-2010099368-A1 | OCULAR IMPLANTS COMPRISING KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20090286773-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286773-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286773-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267497-A1 | KINASE INHIBITORS | PTK2, MAP3K6, MAP3K20 | FLT3 380/4885MEN1 3831/4885KMT2A 1670/4885 |
| US-20090286773-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | FLT3 380/4885MEN1 3831/4885KMT2A 1670/4885 |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | FLT3 298/4885MEN1 3222/4885KMT2A 1161/4885 |
| US-20120238558-A9 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | FLT3 380/4885MEN1 3831/4885KMT2A 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.